AORT vs BBNX: stock comparison and AI forecast
Artivion, Inc. (AORT) and Beta Bionics, Inc. (BBNX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
AORT Artivion, Inc.
- Price
- $20.64 -13.3% · 6M
- Market Cap
- $1.01B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
BBNX Beta Bionics, Inc.
- Price
- $16.95 +72.1% · 6M
- Market Cap
- $922M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- AORT and BBNX have similar market capitalizations ($1.01B and $922M).
- Over the last six months BBNX returned +72.1% and AORT -13.3%.
- AORT carries 0.97 times debt per unit of equity, against 0.11 times for BBNX.
- Both companies share the SEC industry classification Surgical & Medical Instruments & Apparatus.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | AORT | BBNX |
|---|---|---|
| Market Cap | $1.01B | $922M |
| P/B Ratio | 2.25x | 2.30x |
| EPS | $-0.08 | $-2.14 |
| Book Value/Share | $9.19 | $7.38 |
| Revenue/Share | $9.88 | $2.34 |
| FCF/Share | $-0.91 | $-1.21 |
Profitability & Margins
| Metric | AORT | BBNX |
|---|---|---|
| ROE | – | -20.7% |
| ROA | – | -18.7% |
| ROIC | – | -22.5% |
| Gross Margin | 63.3% | 58.6% |
| Operating Margin | 2.4% | -72.8% |
| Net Margin | – | -65.3% |
| EBT Margin | -2.3% | -72.8% |
| Tax Rate | -63.8% | – |
Financial Health
| Metric | AORT | BBNX |
|---|---|---|
| Current Ratio | 4.42x | 8.92x |
| Quick Ratio | 3.02x | 8.22x |
| D/E Ratio | 0.97x | 0.11x |
| Financial Leverage | – | 1.11x |
| Interest Coverage | 0.5x | – |
| Working Capital | $262M | $260M |
Cash Flow
| Metric | AORT | BBNX |
|---|---|---|
| Operating Cash Flow | $15M | -$59M |
| Free Cash Flow | -$44M | -$66M |
| Capital Spending | -$59M | -$7M |
| OCF Growth YoY | -51.1% | – |
| FCF Growth YoY | -353.6% | – |
| FCF/Sales | -9.2% | -51.8% |
| CapEx/Sales | 12.3% | 5.2% |
Operational Efficiency
| Metric | AORT | BBNX |
|---|---|---|
| Asset Turnover | – | 0.29x |
| Receivables Turnover | 5.1x | 6.2x |
| Inventory Turnover | 1.6x | 2.3x |
| Fixed Assets Turnover | 5.9x | 10.8x |
| Days Sales Outstanding | 72 days | 59 days |
| Days Inventory | 221 days | 159 days |
| Payables Period | 36 days | 32 days |
| Cash Conversion Cycle | 257 days | 186 days |
Income Statement
| Metric | AORT | BBNX |
|---|---|---|
| Total Revenue | $482M | $127M |
| Operating Income | $11M | -$93M |
| Net Income | – | -$83M |
| R&D Expense | $37M | $43M |
| SG&A Expense | $261M | $179M |
| Cost of Goods Sold | $177M | $53M |
Dividend & Shareholder Information
| Metric | AORT | BBNX |
|---|---|---|
| Shares Outstanding | 49M | 54M |
AORT vs BBNX: stock comparison and AI forecast
Which is bigger, AORT or BBNX?
AORT and BBNX have similar market capitalizations ($1.01B and $922M).
Which stock performed better over the last six months, AORT or BBNX?
Over the last six months BBNX returned +72.1% and AORT -13.3%.
Which one does Intratio's AI model rank higher, AORT or BBNX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.